You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

Quetiapine, clozapine, and olanzapine in the treatment of tardive dyskinesia induced by first-generation antipsychotics: a 124-week case report

Sacchetti, E.a b c d; Valsecchi, P.b c

International Clinical Psychopharmacology:
Case Reports

Our report of a patient with severe tardive dyskinesia (TD) who has been exposed to both typical antipsychotic and clozapine, olanzapine and quetiapine during a 124-week follow-up period supports the possible beneficial effect of atypical antipsychotics on pre-existing symptoms of TD. Persistently high AIMS scores during all the periods of treatment with typical antipsychotics contrast strongly with the drop in scores that occurres in strict chronological sequence after switching to both clozapine (45%), olanzapine (27.8%) and quetiapine (85%). Since the reversal to haloperidol from the three atypical agents was systemically associated with a return to high AIMS scores, it seems likely that the improvement noted with clozapine, olanzapine and quetiapine represents a temporary symptomatic effect rather than a sustained resolution of the disorder. The olanzapine–clozapine–quetiapine rank order of increasing effectiveness against TD symptoms suggests that this property, although shared by the atypical antipsychotics, is to some degree drug-specific. Patient- and/or drug-dependent mechanisms may be involved in this gradient of effect.

Author Information

aPsychiatry, Brescia University School of Medicine

bUniversity Psychiatric Unit, Brescia University School of Medicine and Brescia Spedali Civili, Brescia, Italy

cDepartment of Mental Health, Brescia Spedali Civili, Brescia, Italy

dBrescia University and EULO Center on Behavioural and Neurodegenerative Disorders

Correspondence and requests for reprints to Emilio Sacchetti, University Psychiatric Unit, Spedali Civili, p. le Spedali Civili 1, 25133 Brescia, Italy

Tel: +39 30 3995233; fax: +39 30 3384089


Received 7 July 2003 Accepted 17 July 2003

© 2003 Lippincott Williams & Wilkins, Inc.